title: Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients.
abstract: Miglitol, a pseudomonosaccharide alpha-glucosidase inhibitor (alphaGI), was more effective at reducing blood glucose levels at 30 and 60 min after a meal than voglibose. Speculating that miglitol administered even after the start of a meal may be effective, we evaluated the timing of administration of miglitol on the plasma glucose and serum insulin levels in 13 type 2 diabetic patients. Miglitol was administered in four different intake manners in each patient (control: no miglitol; intake 1: just before breakfast; intake 2: 15 min after the beginning of breakfast; intake 3: 30 min after the beginning of breakfast). The area under the curve (AUC) of plasma glucose was significantly decreased under all the intake conditions, as compared with the AUC in the control. The AUC of serum insulin tended to be lower in all the three groups than in the control, although the differences were not statistically significant. Thus, miglitol administered anytime within 30 min after the start of a meal is effective for glycemic control. These results suggest that if patients miss taking miglitol at the beginning of a meal, they can still take the drug until 30 min after starting their meal.
authors.affiliation: Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Yokohama, Japan.
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Aoki
authors.forename: Akinobu
authors.initials: A
authors.lastname: Nakamura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ito
authors.forename: Uru
authors.initials: U
authors.lastname: Nezu
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Iwasaki
authors.forename: Mayumi
authors.initials: M
authors.lastname: Takahashi
authors.forename: Mari
authors.initials: M
authors.lastname: Kimura
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Terauchi
mesh_terms: D017485:1-Deoxynojirimycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001786:Blood Glucose / Q000187:drug effects; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D050112:Imino Pyranoses / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged
chemical_list: D017485:1-Deoxynojirimycin; D001786:Blood Glucose; D004791:Enzyme Inhibitors; D006442:Glycated Hemoglobin; D065089:Glycoside Hydrolase Inhibitors; D050112:Imino Pyranoses; D007328:Insulin; C045621:miglitol